146 related articles for article (PubMed ID: 10049189)
1. Dendritic cell-based immunotherapy of renal cell carcinoma.
Thurnher M; Rieser C; Höltl L; Papesh C; Ramoner R; Bartsch G
Urol Int; 1998; 61(2):67-71. PubMed ID: 10049189
[TBL] [Abstract][Full Text] [Related]
2. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells.
Höltl L; Rieser C; Papesh C; Ramoner R; Herold M; Klocker H; Radmayr C; Stenzl A; Bartsch G; Thurnher M
J Urol; 1999 Mar; 161(3):777-82. PubMed ID: 10022683
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells.
Höltl L; Zelle-Rieser C; Gander H; Papesh C; Ramoner R; Bartsch G; Rogatsch H; Barsoum AL; Coggin JH; Thurnher M
Clin Cancer Res; 2002 Nov; 8(11):3369-76. PubMed ID: 12429623
[TBL] [Abstract][Full Text] [Related]
4. Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma.
Kim JH; Lee Y; Bae YS; Kim WS; Kim K; Im HY; Kang WK; Park K; Choi HY; Lee HM; Baek SY; Lee H; Doh H; Kim BM; Kim CY; Jeon C; Jung CW
Clin Immunol; 2007 Dec; 125(3):257-67. PubMed ID: 17916447
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide.
Höltl L; Ramoner R; Zelle-Rieser C; Gander H; Putz T; Papesh C; Nussbaumer W; Falkensammer C; Bartsch G; Thurnher M
Cancer Immunol Immunother; 2005 Jul; 54(7):663-70. PubMed ID: 15918076
[TBL] [Abstract][Full Text] [Related]
6. Dendritic cell immunotherapy for patients with metastatic renal cell carcinoma: University of Tokyo experience.
Azuma T; Horie S; Tomita K; Takahashi T; Tanaka Y; Kashiwase K; Nieda M; Takeuchi T; Ohta N; Shibata Y; Hirai H; Kitamura T
Int J Urol; 2002 Jun; 9(6):340-6. PubMed ID: 12110099
[TBL] [Abstract][Full Text] [Related]
7. [Therapeutic efficacy of dendritic cells pulsed by autologous tumor cell lysate in combination with CIK cells on advanced renal cell carcinoma].
Wang H; Feng F; Zhu M; Wang R; Wang X; Wu Y; Zhuang Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2015 Jan; 31(1):67-71. PubMed ID: 25575061
[TBL] [Abstract][Full Text] [Related]
8. Mature dendritic cells induce T-helper type-1-dominant immune responses in patients with metastatic renal cell carcinoma.
Rieser C; Ramoner R; Höltl L; Rogatsch H; Papesh C; Stenzl A; Bartsch G; Thurnher M
Urol Int; 1999; 63(3):151-9. PubMed ID: 10738185
[TBL] [Abstract][Full Text] [Related]
9. Immune response induced in vitro by CD16- and CD16+ monocyte-derived dendritic cells in patients with metastatic renal cell carcinoma treated with dendritic cell vaccines.
Arroyo JC; Gabilondo F; Llorente L; Meraz-Ríos MA; Sánchez-Torres C
J Clin Immunol; 2004 Jan; 24(1):86-96. PubMed ID: 14997038
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study.
Pandha HS; John RJ; Hutchinson J; James N; Whelan M; Corbishley C; Dalgleish AG
BJU Int; 2004 Aug; 94(3):412-8. PubMed ID: 15291878
[TBL] [Abstract][Full Text] [Related]
11. Immune responses in patients with metastatic renal cell carcinoma treated with dendritic cells pulsed with tumor lysate.
Soleimani A; Berntsen A; Svane IM; Pedersen AE
Scand J Immunol; 2009 Nov; 70(5):481-9. PubMed ID: 19874553
[TBL] [Abstract][Full Text] [Related]
12. Telomerase pulsed dendritic cells for immunotherapy for renal cell carcinoma.
Sievers E; Albers P; Schmidt-Wolf IG; Märten A
J Urol; 2004 Jan; 171(1):114-9. PubMed ID: 14665857
[TBL] [Abstract][Full Text] [Related]
13. Preliminary analysis of patients with progressive renal cell carcinoma vaccinated with CA9-peptide-pulsed mature dendritic cells.
Bleumer I; Tiemessen DM; Oosterwijk-Wakka JC; Völler MC; De Weijer K; Mulders PF; Oosterwijk E
J Immunother; 2007 Jan; 30(1):116-22. PubMed ID: 17198090
[TBL] [Abstract][Full Text] [Related]
14. Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients.
Wierecky J; Müller MR; Wirths S; Halder-Oehler E; Dörfel D; Schmidt SM; Häntschel M; Brugger W; Schröder S; Horger MS; Kanz L; Brossart P
Cancer Res; 2006 Jun; 66(11):5910-8. PubMed ID: 16740731
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical phase I/II trial.
Märten A; Flieger D; Renoth S; Weineck S; Albers P; Compes M; Schöttker B; Ziske C; Engelhart S; Hanfland P; Krizek L; Faber C; von Ruecker A; Müller S; Sauerbruch T; Schmidt-Wolf IG
Cancer Immunol Immunother; 2002 Dec; 51(11-12):637-44. PubMed ID: 12439609
[TBL] [Abstract][Full Text] [Related]
16. Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: implications for live kidney cancer vaccines.
Mulders P; Tso CL; Gitlitz B; Kaboo R; Hinkel A; Frand S; Kiertscher S; Roth MD; deKernion J; Figlin R; Belldegrun A
Clin Cancer Res; 1999 Feb; 5(2):445-54. PubMed ID: 10037196
[TBL] [Abstract][Full Text] [Related]
17. A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma.
Gitlitz BJ; Belldegrun AS; Zisman A; Chao DH; Pantuck AJ; Hinkel A; Mulders P; Moldawer N; Tso CL; Figlin RA
J Immunother; 2003; 26(5):412-9. PubMed ID: 12973030
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy against metastatic renal cell carcinoma with mature dendritic cells.
Matsumoto A; Haraguchi K; Takahashi T; Azuma T; Kanda Y; Tomita K; Kurokawa M; Ogawa S; Takahashi K; Chiba S; Kitamura T
Int J Urol; 2007 Apr; 14(4):277-83. PubMed ID: 17470153
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma--a report of ten cases].
Wang H; Zhou FJ; Wang QJ; Qin ZK; Huang LX; Liu ZW; Han H; Li YQ; Chen SP; Xia JC
Ai Zheng; 2006 May; 25(5):625-30. PubMed ID: 16687087
[TBL] [Abstract][Full Text] [Related]
20. Results of the ADAPT Phase 3 Study of Rocapuldencel-T in Combination with Sunitinib as First-Line Therapy in Patients with Metastatic Renal Cell Carcinoma.
Figlin RA; Tannir NM; Uzzo RG; Tykodi SS; Chen DYT; Master V; Kapoor A; Vaena D; Lowrance W; Bratslavsky G; DeBenedette M; Gamble A; Plachco A; Norris MS; Horvatinovich J; Tcherepanova IY; Nicolette CA; Wood CG;
Clin Cancer Res; 2020 May; 26(10):2327-2336. PubMed ID: 32034074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]